164 lines
No EOL
61 KiB
XML
164 lines
No EOL
61 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK540980" /><meta name="ncbi_domain" content="statpearls" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK540980/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Amoxapine - StatPearls - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="StatPearls [Internet]" /><meta name="citation_title" content="Amoxapine" /><meta name="citation_publisher" content="StatPearls Publishing" /><meta name="citation_date" content="2023/11/18" /><meta name="citation_author" content="Sayeda Abbas" /><meta name="citation_author" content="Raman Marwaha" /><meta name="citation_pmid" content="31082024" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK540980/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Amoxapine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="StatPearls Publishing" /><meta name="DC.Contributor" content="Sayeda Abbas" /><meta name="DC.Contributor" content="Raman Marwaha" /><meta name="DC.Date" content="2023/11/18" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK540980/" /><meta name="description" content="Amoxapine is classified as a second-generation tricyclic dibenzoxazepine antidepressant approved by the U.S. Food and Drug Administration (FDA). This medication is typically prescribed for managing treatment-resistant or persistent depression. Amoxapine is indicated for use in cases of depression accompanied by other psychiatric issues such as anxiety, agitation, psychosis, neurosis, or recurrent depression. The objective of this activity is to familiarize medical practitioners with the appropriate usage of amoxapine and its dosing guidelines, administration, monitoring instructions, and the adverse effects associated with this drug. This activity also highlights the critical roles of a unified interprofessional team in the treatment of patients using amoxapine for their depression." /><meta name="og:title" content="Amoxapine" /><meta name="og:type" content="book" /><meta name="og:description" content="Amoxapine is classified as a second-generation tricyclic dibenzoxazepine antidepressant approved by the U.S. Food and Drug Administration (FDA). This medication is typically prescribed for managing treatment-resistant or persistent depression. Amoxapine is indicated for use in cases of depression accompanied by other psychiatric issues such as anxiety, agitation, psychosis, neurosis, or recurrent depression. The objective of this activity is to familiarize medical practitioners with the appropriate usage of amoxapine and its dosing guidelines, administration, monitoring instructions, and the adverse effects associated with this drug. This activity also highlights the critical roles of a unified interprofessional team in the treatment of patients using amoxapine for their depression." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK540980/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/statpearls/article-17473/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK540980/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B756E7D855FB100000000009F0087.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK540980_"><span class="title" itemprop="name">Amoxapine</span></h1><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Sayeda Abbas</span><sup>1</sup>; <span itemprop="author">Raman Marwaha</span><sup>2</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Avalon University School of Medicine</div><div class="affiliation"><sup>2</sup> Case Western Reserve Un/MetroHealth MC</div><p class="small">Last Update: <span itemprop="dateModified">November 18, 2023</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="article-17473.s1"><h2 id="_article-17473_s1_">Continuing Education Activity</h2><p>Amoxapine is classified as a second-generation tricyclic dibenzoxazepine antidepressant approved by the U.S. Food and Drug Administration (FDA). This medication is typically prescribed for managing treatment-resistant or persistent depression. Amoxapine is indicated for use in cases of depression accompanied by other psychiatric issues such as anxiety, agitation, psychosis, neurosis, or recurrent depression. The objective of this activity is to familiarize medical practitioners with the appropriate usage of amoxapine and its dosing guidelines, administration, monitoring instructions, and the adverse effects associated with this drug. This activity also highlights the critical roles of a unified interprofessional team in the treatment of patients using amoxapine for their depression.</p><p>
|
||
<b>Objectives:</b>
|
||
<ul><li class="half_rhythm"><div>Identify appropriate patient candidates for amoxapine therapy, considering their clinical history, comorbid psychiatric conditions, and resistance to previous treatments.</div></li><li class="half_rhythm"><div>Differentiate amoxapine from other antidepressants, understanding its unique mechanisms of action, adverse effect profile, and potential interactions with other medications.</div></li><li class="half_rhythm"><div>Screen patients for contraindications, allergies, and potential risk factors associated with amoxapine use, such as seizure disorders or cardiac issues.</div></li><li class="half_rhythm"><div>Collaborate with other healthcare professionals, such as psychiatrists, toxicologists, and pharmacists, to ensure coordinated and comprehensive care for patients receiving amoxapine.</div></li></ul>
|
||
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=17473&utm_source=pubmed&utm_campaign=reviews&utm_content=17473" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
||
</p></div><div id="article-17473.s2"><h2 id="_article-17473_s2_">Indications</h2><p>
|
||
<b>FDA-Approved Indications</b>
|
||
</p><p>Amoxapine is classified as a second-generation tricyclic dibenzoxazepine antidepressant approved by the U.S. Food and Drug Administration (FDA). This medication is typically used as a second- or third-line treatment option when selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) have failed to control depression. Thus, amoxapine is indicated for managing treatment-resistant depression when the first- and second-line medications have proven ineffective in alleviating symptoms. Amoxapine is indicated for use in cases of depression accompanied by other psychiatric issues such as anxiety, agitation, psychosis, neurosis, or recurrent depression.<a class="bk_pop" href="#article-17473.r1">[1]</a><a class="bk_pop" href="#article-17473.r2">[2]</a></p><p>
|
||
<b>Off-Label Uses</b>
|
||
</p><p>Research conducted in mice has shown that amoxapine can reduce the production of amyloid-beta chains associated with Alzheimer disease by targeting the serotonin-6 (HTR-6, 5-HT-6) receptor.<a class="bk_pop" href="#article-17473.r3">[3]</a> Multiple studies have shown that amoxapine can reduce the incidence of diarrhea in patients undergoing chemotherapy, particularly when used in conjunction with irinotecan.<a class="bk_pop" href="#article-17473.r4">[4]</a><a class="bk_pop" href="#article-17473.r5">[5]</a> Furthermore, research has highlighted amoxapine's effectiveness in the management of neuropathic pain.<a class="bk_pop" href="#article-17473.r6">[6]</a></p></div><div id="article-17473.s3"><h2 id="_article-17473_s3_">Mechanism of Action</h2><p>Amoxapine, a second-generation tricyclic dibenzoxazepine antidepressant, primarily functions by inhibiting the reuptake of norepinephrine in neuronal synapses. The drug exhibits minimal effect on the histamine H1 receptor and serotonin receptors, except for the serotonin-6 receptor (HTR-6, 5-HT-6).<a class="bk_pop" href="#article-17473.r7">[7]</a><a class="bk_pop" href="#article-17473.r8">[8]</a><a class="bk_pop" href="#article-17473.r9">[9]</a> Furthermore, amoxapine also acts as a dopamine (DA) receptor antagonist, specifically targeting D2 and D4 receptors.<a class="bk_pop" href="#article-17473.r10">[10]</a></p><p>
|
||
<b>Pharmacokinetics</b>
|
||
</p><p>
|
||
<b>Absorption:</b> Amoxapine is rapidly absorbed in the body after oral administration. The time to peak plasma concentration for amoxapine is approximately 90 minutes.</p><p>
|
||
<b>Distribution:</b> Amoxapine exhibits a high plasma protein binding of approximately 90%.</p><p>
|
||
<b>Metabolism:</b> Amoxapine undergoes hepatic metabolism primarily via the CYP2D6 enzyme, leading to the formation of 2 active metabolites—7-hydroxy-amoxapine and 8-hydroxy-amoxapine. These active metabolites have been shown to reduce the incidence of diarrhea in patients after administering irinotecan chemotherapy. Research findings demonstrated that these metabolites effectively reduced tumor growth in patients.<a class="bk_pop" href="#article-17473.r5">[5]</a><a class="bk_pop" href="#article-17473.r11">[11]</a></p><p>
|
||
<b>Elimination:</b> Research indicates that the active metabolite, 8-hydroxy-amoxapine, has a half-life of 30 hours, whereas the drug has a half-life of 8 hours. The primary route of drug elimination from the body is through urine, with a minor fraction excreted in the feces.<a class="bk_pop" href="#article-17473.r2">[2]</a></p></div><div id="article-17473.s4"><h2 id="_article-17473_s4_">Administration</h2><p>
|
||
<b>Available Dosage Forms and Strengths</b>
|
||
</p><p>Amoxapine is available in oral tablet formulations, with strengths of 25 mg, 50 mg, 100 mg, and 150 mg doses.</p><p>
|
||
<b>Adult Dosage</b>
|
||
</p><p>Amoxapine is typically administered orally at a starting dose of 100 mg, with the option to increase the dosage up to a maximum of 300 mg. The normal therapeutic dose for depression is between 200 and 300 mg, usually taken orally at bedtime.<a class="bk_pop" href="#article-17473.r12">[12]</a><a class="bk_pop" href="#article-17473.r13">[13]</a><a class="bk_pop" href="#article-17473.r14">[14]</a> Amoxapine can be administered daily to patients either as a single dose or 2 equally divided doses.<a class="bk_pop" href="#article-17473.r15">[15]</a> However, due to the prolonged half-life of the active drug metabolites, a single daily dose of amoxapine is often preferred over divided doses for more effective treatment. Antidepressant benefits from amoxapine may become noticeable within just 7 days, and more than 80% of patients experience significant improvement within 2 weeks.<a class="bk_pop" href="#article-17473.r7">[7]</a> The maximum recommended dosage of amoxapine for outpatient settings is 400 mg daily, whereas, for hospitalized patients with no history of seizures, it is 600 mg daily.</p><p>
|
||
<b>Maintenance Dosage</b>
|
||
</p><p>The recommended maintenance dose for amoxapine is the minimum effective dose needed to maintain remission. If symptoms reappear, the dosage should be increased to the previous level until they are under control. Notably, it is recommended to take a single dose of ≤300 mg at bedtime for maintenance therapy.</p><p>
|
||
<b>Specific Patient Populations</b>
|
||
</p><p>
|
||
<b>Hepatic impairment:</b> The product labeling does not specify dosage adjustments for hepatic impairment. However, it is advisable to exercise caution when administering amoxapine to these patients, considering its liver-dependent metabolism.<a class="bk_pop" href="#article-17473.r11">[11]</a></p><p>
|
||
<b>Renal impairment:</b> The product labeling does not contain specific guidance on dosage adjustments for renal impairment. Thus, it is crucial to exercise caution when prescribing amoxapine to patients with renal impairment, as its primary elimination route is through the kidneys.</p><p>
|
||
<b>Pregnancy considerations:</b> Amoxapine was previously classified by the FDA as a pregnancy category C drug. Studies on animals revealed fetotoxic effects, including intrauterine death, decreased birth weight, and stillbirth, occurring at oral doses 3 to 10 times higher than the human dose. There is limited availability of well-controlled studies involving pregnant women. Consequently, amoxapine use during pregnancy should be approached cautiously. Decisions regarding medication use in pregnant women should be made judiciously, taking into account a careful assessment of the potential benefits and risks to the fetus.<a class="bk_pop" href="#article-17473.r16">[16]</a></p><p>
|
||
<b>Breastfeeding considerations: </b>Limited published data exist on amoxapine use during breastfeeding. Cases of galactorrhea have been observed in non-breastfeeding women using amoxapine. When nursing a newborn or preterm infant, it is advisable to explore alternative agents, such as sertraline, due to its more established safety profile in this context.<a class="bk_pop" href="#article-17473.r17">[17]</a></p><p>
|
||
<b>Pediatric patients:</b> Amoxapine lacks FDA approval for use in pediatric patients.<b></b></p><p>
|
||
<b>Older patients:</b> Clinical studies of amoxapine in individuals 65 and older did not establish whether they exhibit different responses compared to younger subjects. As amoxapine is metabolized by the liver and excreted by the kidney, healthcare providers should exercise caution when prescribing the medication to older patients, considering potential hepatic and renal impairments. According to the American Geriatrics Society (AGS) Beers Criteria, amoxapine is noted for its potent anticholinergic properties. Therefore, its use should be considered only after a meticulous risk-benefit assessment.<a class="bk_pop" href="#article-17473.r18">[18]</a></p></div><div id="article-17473.s5"><h2 id="_article-17473_s5_">Adverse Effects</h2><p>The common adverse effects of amoxapine therapy include, but are not limited to, insomnia, palpitations, tachycardia, hypotension, and constipation.<a class="bk_pop" href="#article-17473.r19">[19]</a><a class="bk_pop" href="#article-17473.r20">[20]</a><a class="bk_pop" href="#article-17473.r2">[2]</a> Furthermore, research has indicated that amoxapine may trigger hypomanic states in individuals with underlying bipolar disorder.<a class="bk_pop" href="#article-17473.r19">[19]</a> Amoxapine has been observed to induce noradrenaline-mediated contraction of the urethra in guinea pigs and rats in various laboratory studies, leading to elevated urethral resistance.<a class="bk_pop" href="#article-17473.r21">[21]</a><a class="bk_pop" href="#article-17473.r22">[22]</a> In addition, the drug has been associated with instances of painful ejaculations relieved by the administration of tamsulosin.<a class="bk_pop" href="#article-17473.r23">[23]</a> Notably, tricyclic antidepressants (TCAs), including amoxapine, are correlated with an increased risk of seizures, especially in older patients and those with epilepsy.<a class="bk_pop" href="#article-17473.r24">[24]</a><a class="bk_pop" href="#article-17473.r25">[25]</a> Therefore, it is recommended to use SSRIs or SNRIs in patients with a history of epilepsy and seizures.</p><p>Amoxapine's anticholinergic properties can result in adverse effects such as sedation, dry mouth, delirium, and drug-induced Parkinsonism, particularly among older patients.<a class="bk_pop" href="#article-17473.r26">[26]</a> In a few cases, amoxapine has been associated with QTc interval prolongation.<a class="bk_pop" href="#article-17473.r27">[27]</a> Notably, as amoxapine may lead to urinary retention, it is important to exercise caution when prescribing the drug for patients with bladder outlet obstruction.<a class="bk_pop" href="#article-17473.r28">[28]</a></p><p>
|
||
<b>Drug-Drug Interactions</b>
|
||
</p><ul><li class="half_rhythm"><div>Amoxapine has the potential to enhance central nervous system depression caused by barbiturates and alcohol. Therefore, concurrent use of the drug with barbiturates and alcohol should be avoided.<a class="bk_pop" href="#article-17473.r29">[29]</a></div></li></ul><ul><li class="half_rhythm"><div>In a subset of the Caucasian population who are poor metabolizers with reduced CYP2D6 activity, TCAs, such as amoxapine, have increased plasma concentrations.</div></li></ul><ul><li class="half_rhythm"><div>Dose reduction may be necessary when TCAs, such as amoxapine, are combined with CYP2D6-inhibiting drugs, including quinidine, cimetidine, phenothiazines, propafenone, and flecainide.<a class="bk_pop" href="#article-17473.r30">[30]</a></div></li></ul><ul><li class="half_rhythm"><div>All SSRIs exhibit varying degrees of CYP2D6 inhibition. Therefore, clinicians should exercise caution when combining TCAs with SSRIs or making transitions between these 2 classes of medications. In addition, when switching from fluoxetine to amoxapine, a substantial time interval is necessary due to the extended half-life of fluoxetine, which is at least 5 weeks. This precaution helps prevent potential interactions and ensures the safe use of medications.<a class="bk_pop" href="#article-17473.r31">[31]</a></div></li></ul></div><div id="article-17473.s6"><h2 id="_article-17473_s6_">Contraindications</h2><p>Amoxapine is contraindicated in patients with a known hypersensitivity to dibenzoxazepine compounds. The primary mechanism of action of amoxapine involves inhibiting the presynaptic reuptake of norepinephrine. Therefore, patients are advised against taking amoxapine concurrently with other antidepressants or medications, such as monoamine oxidase inhibitors (MAOIs), that produce similar effects. Patients should avoid taking the drug within a 14-day window of taking other antidepressants. This period allows the prior antidepressant to be eliminated from the system before initiating amoxapine or any other TCA. Furthermore, due to amoxapine's potential for QTc prolongation, it is not prescribed to patients with extended QTc intervals or those experiencing acute myocardial infarction, as it may worsen their symptoms.<a class="bk_pop" href="#article-17473.r27">[27]</a></p><p>
|
||
<b>Box Warning</b>
|
||
</p><p>Amoxapine has an FDA black box warning for increased suicidality risk in individuals aged 24 and younger and aged 65 and older. Amoxapine is not recommended for the treatment of pediatric depression.<a class="bk_pop" href="#article-17473.r32">[32]</a></p><p>
|
||
<b>Warnings and Precautions</b>
|
||
</p><p>Although amoxapine is effective for certain conditions, it demands vigilant consideration of particular concerns to mitigate potential risks and adhere to essential safety measures associated with its usage.</p><p>
|
||
<b>Extrapyramidal adverse effects:</b> Amoxapine's ability to block dopamine receptors increases the risk of experiencing extrapyramidal adverse effects and tardive dyskinesia.</p><p>
|
||
<b>Angle-closure glaucoma:</b> Amoxapine's potential for inducing pupillary dilation is a crucial concern, especially for patients with anatomically narrow angles, as it heightens the risk of angle-closure glaucoma.</p><p>
|
||
<b>Seizures:</b> TCAs are also contraindicated in patients with a history of epilepsy or seizures. Instead, individuals who are at risk of seizures should consider taking SSRIs or SNRIs instead of amoxapine, as research indicates that amoxapine may slightly increase the risk of seizures.<a class="bk_pop" href="#article-17473.r25">[25]</a></p><p>
|
||
<b>Hepatic impairment:</b> As amoxapine is metabolized in the liver, it is imperative to exercise extreme caution when prescribing this medication to patients with hepatic impairment or active liver disease.<a class="bk_pop" href="#article-17473.r11">[11]</a></p><p>
|
||
<b>Electroconvulsive therapy:</b> The concurrent administration of amoxapine and electroshock therapy may heighten the associated risks of electroconvulsive therapy. </p><p>
|
||
<b>Neuroleptic malignant syndrome (NMS):</b> NMS can arise as a result of antipsychotic drugs, including amoxapine. Clinical manifestations of NMS encompass hyperpyrexia, muscle rigidity, altered mental status, and signs of autonomic instability, such as irregular pulse or labile blood pressure, diaphoresis, and cardiac dysrhythmias. The management of NMS entails the immediate discontinuation of causative medications, including amoxapine, along with vigilant medical supervision and the prompt implementation of supportive care measures.<a class="bk_pop" href="#article-17473.r33">[33]</a><a class="bk_pop" href="#article-17473.r34">[34]</a></p><p>
|
||
<b>Bipolar disorder:</b> The initial manifestation of bipolar disorder can often resemble a major depressive episode. However, a concern prevails that using antidepressant monotherapy, such as amoxapine, can trigger a manic episode in individuals with a predisposition to bipolar disorder. Therefore, it is essential to conduct a thorough assessment of the patient's personal and family history of bipolar disorder and suicide before initiating antidepressant treatment.<a class="bk_pop" href="#article-17473.r35">[35]</a><a class="bk_pop" href="#article-17473.r36">[36]</a></p></div><div id="article-17473.s7"><h2 id="_article-17473_s7_">Monitoring</h2><p>Patients taking amoxapine should undergo regular monitoring for resolution or reduction of symptoms, withdrawal symptoms from abrupt discontinuation, changes in body weight and BMI, blood pressure and blood glucose levels, worsening of depression, the emergence of suicidal thoughts, or unusual behavior at the onset of therapy or during dose adjustments. Older individuals and those with preexisting cardiac disease or hyperthyroidism should undergo a 12-lead electrocardiogram as part of their evaluation. As the older population faces an elevated risk of hyponatremia, necessitating electrolyte monitoring in patients 65 and older is important.<a class="bk_pop" href="#article-17473.r37">[37]</a><b> </b>Clinicians can monitor patient responses using validated questionnaires such as the patient health questionnaire (PHQ-9) and the Hamilton Rating Scale for Depression. Furthermore, it is crucial to remain vigilant for signs of suicidal ideation.<a class="bk_pop" href="#article-17473.r38">[38]</a><a class="bk_pop" href="#article-17473.r39">[39]</a></p></div><div id="article-17473.s8"><h2 id="_article-17473_s8_">Toxicity</h2><p>
|
||
<b>Signs and Symptoms of Overdose</b>
|
||
</p><p>The primary concern for TCA toxicity is the potential development of serotonin syndrome, particularly when the medication is combined with other antidepressants such as SSRIs or SNRIs. Serotonin syndrome is characterized by symptoms such as hyperthermia, hypertension, muscle rigidity, and delirium. </p><p>
|
||
<b>Management of Overdose</b>
|
||
</p><p>In case of TCA or amoxapine overdose, there is no particular antidote available. The primary concern in cases of TCA overdose is ensuring proper respiration and delivering cardiovascular support to patients. Research has demonstrated that, in certain instances, sodium bicarbonate can reduce the incidence of QRS widening.<a class="bk_pop" href="#article-17473.r40">[40]</a> This treatment requires vigilant monitoring of sodium plasma concentrations, as there is a possibility of hypernatremia in patients receiving sodium bicarbonate. However, in the absence of immediate electrolyte changes, the standard protocol involves close monitoring of the patient in the intensive care unit to detect any cardiac abnormalities and ensure adequate hydration to facilitate drug elimination from the system. Analysis of U.S. Poison Control Center data from 2000 to 2014 reveals that amoxapine toxicity may lead to severe complications, including cardiac arrest, renal failure, and intractable seizures.<a class="bk_pop" href="#article-17473.r41">[41]</a> </p><p>In a recent case report, intractable seizures were observed following an amoxapine overdose resulting from a suicide attempt involving the consumption of 3 g of the drug. Despite the administration of intravenous diazepam, levetiracetam, and phenobarbital, the seizures remained uncontrolled. However, the seizures ceased just within 2 minutes of initiating intravenous lipid emulsion (ILE). Although a seizure recurrence occurred 30 minutes after the initial ILE treatment, these seizures were effectively managed through the re-administration of ILE. Therefore, ILE should be considered as a potential intervention for managing severe amoxapine overdose.<a class="bk_pop" href="#article-17473.r42">[42]</a> The prevailing mechanism of lipid emulsion treatment as adjunctive therapy in cases of drug toxicity is based on the hypothesis of lipid shuttling. ILE administration establishes a substantial lipid compartment that efficiently absorbs highly lipid-soluble drugs such as amoxapine, aiding in their removal from the system.<a class="bk_pop" href="#article-17473.r43">[43]</a><b></b></p></div><div id="article-17473.s9"><h2 id="_article-17473_s9_">Enhancing Healthcare Team Outcomes </h2><p>As TCAs, such as amoxapine, are typically reserved as third-line treatments for depression, patients who receive them or are being considered for their use typically exhibit recurrent or reactive depression. This suggests that other medication and treatment approaches have proven ineffective in managing the symptoms of these patients. Consequently, these patients are at an elevated risk of engaging in self-harming and suicidal behaviors. To address these concerns effectively, it is imperative to assemble a cohesive interprofessional healthcare team to oversee their treatment. This team should encompass regular coordination between the patient's primary physician, psychiatrist, and counselors, ensuring adherence to the medication regimen and monitoring the response to treatment. At every office visit, comprehensive assessments for suicidal ideations, plans, or tendencies should be conducted. Appropriate overdose precautions should be initiated if there is any indication that patients pose a risk to themselves or others.<a class="bk_pop" href="#article-17473.r44">[44]</a></p><p>Treatment with amoxapine and other antidepressant medications is most effective when managed by an interprofessional healthcare team responsible for all aspects of the patient's case. This team comprises physicians who prescribe and make regimen-related decisions, specialists who provide in-depth condition-specific expertise, specialized nursing staff who oversee care, ensure patient adherence, and assist with monitoring patient symptoms, and pharmacists who conduct medication reconciliation and dosage verification. A retrospective analysis of data from hospitalized patients with poisoning indicates significant reductions in hospitalization duration, healthcare costs, and mortality rates when medical toxicologists actively participate in patient care.<a class="bk_pop" href="#article-17473.r45">[45]</a> All interprofessional team members, including clinicians (MD, DO, NP, and PA), nurses, specialists, toxicologists, and pharmacists, should collaborate and maintain open communication to ensure optimal care and outcomes related to amoxapine therapy.</p></div><div id="article-17473.s10"><h2 id="_article-17473_s10_">Review Questions</h2><ul><li class="half_rhythm"><div>
|
||
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=17473&utm_source=pubmed&utm_campaign=reviews&utm_content=17473" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
||
</div></li><li class="half_rhythm"><div>
|
||
<a href="https://www.statpearls.com/articlelibrary/commentarticle/17473/?utm_source=pubmed&utm_campaign=comments&utm_content=17473" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Comment on this article.</a>
|
||
</div></li></ul></div><div id="article-17473.s11"><h2 id="_article-17473_s11_">References</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="article-17473.r1">Cugurra F. [Drug therapy and affective disorders: state of the art]. <span><span class="ref-journal">Clin Ter. </span>1995 Oct;<span class="ref-vol">146</span>(10):577-85.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8590559" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8590559</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="article-17473.r2">Kinney JL, Evans RL. Evaluation of amoxapine. <span><span class="ref-journal">Clin Pharm. </span>1982 Sep-Oct;<span class="ref-vol">1</span>(5):417-24.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6764165" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6764165</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="article-17473.r3">Li X, Wang Q, Hu T, Wang Y, Zhao J, Lu J, Pei G. A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets. <span><span class="ref-journal">Sci Rep. </span>2017 Jul 10;<span class="ref-vol">7</span>(1):4983.</span> [<a href="/pmc/articles/PMC5504036/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5504036</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28694424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28694424</span></a>]</div></dd><dt>4.</dt><dd><div class="bk_ref" id="article-17473.r4">Ahmad S, Hughes MA, Yeh LA, Scott JE. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors. <span><span class="ref-journal">J Biomol Screen. </span>2012 Aug;<span class="ref-vol">17</span>(7):957-65.</span> [<a href="/pmc/articles/PMC8284931/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8284931</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22535688" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22535688</span></a>]</div></dd><dt>5.</dt><dd><div class="bk_ref" id="article-17473.r5">Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST. Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. <span><span class="ref-journal">Clin Cancer Res. </span>2014 Jul 01;<span class="ref-vol">20</span>(13):3521-30.</span> [<a href="/pmc/articles/PMC4079752/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4079752</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24780296" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24780296</span></a>]</div></dd><dt>6.</dt><dd><div class="bk_ref" id="article-17473.r6">Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. <span><span class="ref-journal">Pharmacol Rep. </span>2013;<span class="ref-vol">65</span>(6):1611-21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24553009" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24553009</span></a>]</div></dd><dt>7.</dt><dd><div class="bk_ref" id="article-17473.r7">van Wyk EM, Louw DA. Amoxapine in the treatment of depression. A clinical evaluation in ambulant patients. <span><span class="ref-journal">S Afr Med J. </span>1982 Jun 12;<span class="ref-vol">61</span>(24):908-11.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7046092" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7046092</span></a>]</div></dd><dt>8.</dt><dd><div class="bk_ref" id="article-17473.r8">Kapoor R, Peyear TA, Koeppe RE, Andersen OS. Antidepressants are modifiers of lipid bilayer properties. <span><span class="ref-journal">J Gen Physiol. </span>2019 Mar 04;<span class="ref-vol">151</span>(3):342-356.</span> [<a href="/pmc/articles/PMC6400527/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6400527</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30796095" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30796095</span></a>]</div></dd><dt>9.</dt><dd><div class="bk_ref" id="article-17473.r9">Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>1984 Jul;<span class="ref-vol">230</span>(1):94-102.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6086881" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6086881</span></a>]</div></dd><dt>10.</dt><dd><div class="bk_ref" id="article-17473.r10">Reeves KC, Virk S, Niedermier J, Duchemin AM. Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. <span><span class="ref-journal">Ther Adv Psychopharmacol. </span>2013 Dec;<span class="ref-vol">3</span>(6):340-2.</span> [<a href="/pmc/articles/PMC3840811/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3840811</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24294487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24294487</span></a>]</div></dd><dt>11.</dt><dd><div class="bk_ref" id="article-17473.r11"><span class="ref-journal">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</span> National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Mar 2, 2016. Amoxapine. [<a href="/pmc/articles/PMC547852/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC547852</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31643838" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31643838</span></a>]</div></dd><dt>12.</dt><dd><div class="bk_ref" id="article-17473.r12">Ban TA, Fujimori M, Petrie WM, Ragheb M, Wilson WH. Systematic studies with amoxapine, a new antidepressant. <span><span class="ref-journal">Int Pharmacopsychiatry. </span>1982;<span class="ref-vol">17</span>(1):18-27.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7045016" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7045016</span></a>]</div></dd><dt>13.</dt><dd><div class="bk_ref" id="article-17473.r13">Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. <span><span class="ref-journal">Neuropsychopharmacology. </span>2005 Dec;<span class="ref-vol">30</span>(12):2236-44.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15956984" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15956984</span></a>]</div></dd><dt>14.</dt><dd><div class="bk_ref" id="article-17473.r14">Ban TA, Wilson WH, McEvoy JP. Amoxapine: a review of literature. <span><span class="ref-journal">Int Pharmacopsychiatry. </span>1980;<span class="ref-vol">15</span>(3):166-70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7016801" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7016801</span></a>]</div></dd><dt>15.</dt><dd><div class="bk_ref" id="article-17473.r15">Ragheb M, Wilson WH, Ban TA, Brannen JO. Amoxapine: once versus divided daily doses in neurotic and endogenous depression. <span><span class="ref-journal">J Clin Psychiatry. </span>1981 Aug;<span class="ref-vol">42</span>(8):318-21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7019201" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7019201</span></a>]</div></dd><dt>16.</dt><dd><div class="bk_ref" id="article-17473.r16">ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <span><span class="ref-journal">Obstet Gynecol. </span>2008 Apr;<span class="ref-vol">111</span>(4):1001-20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18378767" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18378767</span></a>]</div></dd><dt>17.</dt><dd><div class="bk_ref" id="article-17473.r17"><span class="ref-journal">Drugs and Lactation Database (LactMed®) [Internet].</span> National Institute of Child Health and Human Development; Bethesda (MD): Apr 18, 2022. Amoxapine. [<a href="https://pubmed.ncbi.nlm.nih.gov/30000242" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30000242</span></a>]</div></dd><dt>18.</dt><dd><div class="bk_ref" id="article-17473.r18">By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. <span><span class="ref-journal">J Am Geriatr Soc. </span>2023 Jul;<span class="ref-vol">71</span>(7):2052-2081.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37139824" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37139824</span></a>]</div></dd><dt>19.</dt><dd><div class="bk_ref" id="article-17473.r19">Aono T, Kaneko M, Numata Y, Takahashi Y, Yamamoto T, Kumashiro H. Effects of amoxapine, a new antidepressant, on pseudoneurotic schizophrenia. <span><span class="ref-journal">Folia Psychiatr Neurol Jpn. </span>1981;<span class="ref-vol">35</span>(2):115-21.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7026396" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7026396</span></a>]</div></dd><dt>20.</dt><dd><div class="bk_ref" id="article-17473.r20">Hekimian LJ, Weise CC, Friedhoff AJ. Onset of action of amoxapine and doxepin in outpatients with "mixed anxiety/depression". <span><span class="ref-journal">J Clin Psychiatry. </span>1983 Jul;<span class="ref-vol">44</span>(7):248-52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6863224" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6863224</span></a>]</div></dd><dt>21.</dt><dd><div class="bk_ref" id="article-17473.r21">Obara K, Imanaka S, Fukuhara H, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Evaluation of the potentiating effects of antidepressants on the contractile response to noradrenaline in guinea pig urethra smooth muscles. <span><span class="ref-journal">Clin Exp Pharmacol Physiol. </span>2019 May;<span class="ref-vol">46</span>(5):444-455.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30737814" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30737814</span></a>]</div></dd><dt>22.</dt><dd><div class="bk_ref" id="article-17473.r22">Obara K, Michino M, Ito M, Ao L, Sawada A, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Evaluation of Antidepressant Effects on Recovery of Electrical Field Stimulation-Induced Contractions that have been Suppressed by Clonidine in Isolated Rat Vas Deferens. <span><span class="ref-journal">Pharmacology. </span>2019;<span class="ref-vol">103</span>(3-4):189-201.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30695779" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30695779</span></a>]</div></dd><dt>23.</dt><dd><div class="bk_ref" id="article-17473.r23">Demyttenaere K, Huygens R. Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. <span><span class="ref-journal">Eur Neuropsychopharmacol. </span>2002 Aug;<span class="ref-vol">12</span>(4):337-41.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12126873" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12126873</span></a>]</div></dd><dt>24.</dt><dd><div class="bk_ref" id="article-17473.r24">Johannessen Landmark C, Henning O, Johannessen SI. Proconvulsant effects of antidepressants - What is the current evidence? <span><span class="ref-journal">Epilepsy Behav. </span>2016 Aug;<span class="ref-vol">61</span>:287-291.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26926001" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26926001</span></a>]</div></dd><dt>25.</dt><dd><div class="bk_ref" id="article-17473.r25">Górska N, Słupski J, Cubała WJ, Wiglusz MS, Gałuszko-Węgielnik M. Antidepressants in epilepsy. <span><span class="ref-journal">Neurol Neurochir Pol. </span>2018 Nov-Dec;<span class="ref-vol">52</span>(6):657-661.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30131174" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30131174</span></a>]</div></dd><dt>26.</dt><dd><div class="bk_ref" id="article-17473.r26">Farzam K, Sabir S, O'Rourke MC. <span class="ref-journal">StatPearls [Internet].</span> StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Antihistamines. [<a href="https://pubmed.ncbi.nlm.nih.gov/30844215" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30844215</span></a>]</div></dd><dt>27.</dt><dd><div class="bk_ref" id="article-17473.r27">Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. <span><span class="ref-journal">Naunyn Schmiedebergs Arch Pharmacol. </span>2010 May;<span class="ref-vol">381</span>(5):385-400.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20229012" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20229012</span></a>]</div></dd><dt>28.</dt><dd><div class="bk_ref" id="article-17473.r28">Serlin DC, Heidelbaugh JJ, Stoffel JT. Urinary Retention in Adults: Evaluation and Initial Management. <span><span class="ref-journal">Am Fam Physician. </span>2018 Oct 15;<span class="ref-vol">98</span>(8):496-503.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30277739" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30277739</span></a>]</div></dd><dt>29.</dt><dd><div class="bk_ref" id="article-17473.r29">Dai Z, Abate MA, Long DL, Smith GS, Halki TM, Kraner JC, Mock AR. Quantifying enhanced risk from alcohol and other factors in polysubstance-related deaths. <span><span class="ref-journal">Forensic Sci Int. </span>2020 Aug;<span class="ref-vol">313</span>:110352.</span> [<a href="/pmc/articles/PMC7374018/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7374018</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32590196" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32590196</span></a>]</div></dd><dt>30.</dt><dd><div class="bk_ref" id="article-17473.r30">Poh BH, Lee JH, Abdul Haium AA, Choo TLJ. Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing? <span><span class="ref-journal">Pediatrics. </span>2020 Jul;<span class="ref-vol">146</span>(1)</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32561613" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32561613</span></a>]</div></dd><dt>31.</dt><dd><div class="bk_ref" id="article-17473.r31">Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics. <span><span class="ref-journal">Prescrire Int. </span>2001 Feb;<span class="ref-vol">10</span>(51):25-31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11503857" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11503857</span></a>]</div></dd><dt>32.</dt><dd><div class="bk_ref" id="article-17473.r32">Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. <span><span class="ref-journal">BMC Psychiatry. </span>2020 Jun 16;<span class="ref-vol">20</span>(1):308.</span> [<a href="/pmc/articles/PMC7298955/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7298955</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32546134" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32546134</span></a>]</div></dd><dt>33.</dt><dd><div class="bk_ref" id="article-17473.r33">Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. <span><span class="ref-journal">Neuropsychiatr Dis Treat. </span>2017;<span class="ref-vol">13</span>:161-175.</span> [<a href="/pmc/articles/PMC5248946/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5248946</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28144147" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28144147</span></a>]</div></dd><dt>34.</dt><dd><div class="bk_ref" id="article-17473.r34">Janati AB, Alghasab N, Osman A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. <span><span class="ref-journal">Case Rep Neurol Med. </span>2012;<span class="ref-vol">2012</span>:183252.</span> [<a href="/pmc/articles/PMC3420485/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3420485</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22953086" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22953086</span></a>]</div></dd><dt>35.</dt><dd><div class="bk_ref" id="article-17473.r35">Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <span><span class="ref-journal">Bipolar Disord. </span>2018 Mar;<span class="ref-vol">20</span>(2):97-170.</span> [<a href="/pmc/articles/PMC5947163/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5947163</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29536616</span></a>]</div></dd><dt>36.</dt><dd><div class="bk_ref" id="article-17473.r36">Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov S, Möller HJ, Kasper S., Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <span><span class="ref-journal">World J Biol Psychiatry. </span>2018 Feb;<span class="ref-vol">19</span>(1):2-58.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29098925" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29098925</span></a>]</div></dd><dt>37.</dt><dd><div class="bk_ref" id="article-17473.r37">Rochoy M, Zakhem-Stachera C, Béné J, Berkhout C, Gautier S., Réseau français des Centres Régionaux de Pharmacovigilance. [Antidepressive agents and hyponatremia: A literature review and a case/non-case study in the French Pharmacovigilance database]. <span><span class="ref-journal">Therapie. </span>2018 Oct;<span class="ref-vol">73</span>(5):389-398.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29773358" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29773358</span></a>]</div></dd><dt>38.</dt><dd><div class="bk_ref" id="article-17473.r38">Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. <span><span class="ref-journal">J Clin Psychiatry. </span>2009;<span class="ref-vol">70 Suppl 6</span>:26-31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19922741" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19922741</span></a>]</div></dd><dt>39.</dt><dd><div class="bk_ref" id="article-17473.r39">Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. <span><span class="ref-journal">BMJ. </span>2022 Aug 02;<span class="ref-vol">378</span>:e067606.</span> [<a href="/pmc/articles/PMC9344377/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9344377</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35918097" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35918097</span></a>]</div></dd><dt>40.</dt><dd><div class="bk_ref" id="article-17473.r40">Kassim T, Mahfood Haddad T, Rakhra A, Kabach A, Qurie A, Selim M, Nayfeh AS, Aly A, Holmberg MJ. A Case of Amitriptyline-induced Myocarditis. <span><span class="ref-journal">Cureus. </span>2018 Jun 19;<span class="ref-vol">10</span>(6):e2840.</span> [<a href="/pmc/articles/PMC6233954/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6233954</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30430045" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30430045</span></a>]</div></dd><dt>41.</dt><dd><div class="bk_ref" id="article-17473.r41">Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. <span><span class="ref-journal">Am J Psychiatry. </span>2017 May 01;<span class="ref-vol">174</span>(5):438-450.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28135844" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28135844</span></a>]</div></dd><dt>42.</dt><dd><div class="bk_ref" id="article-17473.r42">Matsuoka M, Imai T, Iwabuchi S, Kinoshita K. Successful Treatment of Amoxapine-Induced Intractable Seizures With Intravenous Lipid Emulsion. <span><span class="ref-journal">J Emerg Med. </span>2023 Jan;<span class="ref-vol">64</span>(1):62-66.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36450616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36450616</span></a>]</div></dd><dt>43.</dt><dd><div class="bk_ref" id="article-17473.r43">Sohn JT. Half-Life of Lipid Emulsions Used in Lipid Emulsion Treatment for Drug Toxicity. <span><span class="ref-journal">J Emerg Med. </span>2023 Feb;<span class="ref-vol">64</span>(2):253-254.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36906377" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36906377</span></a>]</div></dd><dt>44.</dt><dd><div class="bk_ref" id="article-17473.r44">Buckley NA, McManus PR. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? <span><span class="ref-journal">Drug Saf. </span>1998 May;<span class="ref-vol">18</span>(5):369-81.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9589848" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9589848</span></a>]</div></dd><dt>45.</dt><dd><div class="bk_ref" id="article-17473.r45">Curry SC, Brooks DE, Skolnik AB, Gerkin RD, Glenn S. Effect of a medical toxicology admitting service on length of stay, cost, and mortality among inpatients discharged with poisoning-related diagnoses. <span><span class="ref-journal">J Med Toxicol. </span>2015 Mar;<span class="ref-vol">11</span>(1):65-72.</span> [<a href="/pmc/articles/PMC4371032/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4371032</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25127915" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25127915</span></a>]</div></dd></dl></div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_top_margin">
|
||
<b>Disclosure: </b>Sayeda Abbas declares no relevant financial relationships with ineligible companies.</p></div></dd><dt></dt><dd><div><p class="no_top_margin">
|
||
<b>Disclosure: </b>Raman Marwaha declares no relevant financial relationships with ineligible companies.</p></div></dd></dl></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025, StatPearls Publishing LLC.<p class="small">
|
||
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
|
||
(<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">
|
||
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
||
</a>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
|
||
</p></div><div class="small"><span class="label">Bookshelf ID: NBK540980</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31082024" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31082024</a></span></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK540980&ncbi_domain=statpearls&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK540980/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |